A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea
NCT03276936
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
504
Enrollment
INDUSTRY
Sponsor class
Conditions
Papulopustular Rosacea
Interventions
DRUG:
FMX103 1.5%
Sponsor
Vyne Therapeutics Inc.